Compare Definium Therapeutics Inc. Common Shares (DFTX) vs Skyworks Solutions Inc (SWKS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs Skyworks Solutions Inc — how do they compare? Definium Therapeutics Inc. Common Shares trades at $35.4 (market cap $4.59B), while Skyworks Solutions Inc trades at $79.56 (market cap $12.15B). The key difference: Skyworks Solutions Inc is far larger — about 2.6× Definium Therapeutics Inc. Common Shares's market cap, and Skyworks Solutions Inc pays a 4.13% dividend while Definium Therapeutics Inc. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and Skyworks Solutions Inc for 50 Days on average.
| DFTX | SWKS | |
|---|---|---|
Market Cap | $4.59B | $12.15B |
Volume | 2,103,937 | 7,390,810 |
Sector | Health | Technology |
52-Week High | $48.45 | $91.45 |
52-Week Low | $10.68 | $52.50 |
Typical Hold Time | 0 Days | 50 Days |
Enterprise Value | $3.55B | $12.03B |
Dividend Yield | — | 4.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Skyworks Solutions (SWKS) trades at $83.43, up 0.88% with neutral technical signals. The stock shows declining revenue from $4.8B in 2023 to $4.1B in 2025 and contracting profit margins from 20.59% to 11.67% over the same period. Recent Q2 2026 earnings beat expectations at $1.08 EPS versus $1.03 expected. The pending Qorvo merger, expected to close in 2026 with $500M in synergies, represents a major strategic shift that could enhance scale and market positioning.
While analyst consensus remains bullish (60% buy ratings) with a $78.80 price target, near-term risks include execution challenges with the merger integration and ongoing revenue pressure. The current P/E of 43.23 appears elevated relative to earnings growth trends, suggesting investors should weigh merger benefits against fundamental deterioration.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →
